التفاصيل البيبلوغرافية
| العنوان: |
Amphoteric liposomes |
| Document Number: |
20110293695 |
| تاريخ النشر: |
December 1, 2011 |
| Appl. No: |
12/806342 |
| Application Filed: |
August 09, 2010 |
| مستخلص: |
Amphoteric liposomes are proposed, which comprise positive and negative membrane-based or membrane-forming charge carriers as well as the use of these liposomes. |
| Inventors: |
Panzner, Steffen (Halle, DE); Fankh+e,uml a+ee nel, Stefan (Borsdorf, DE); Essler, Frank (Mainz, DE); Panzner, Cornelia (Halle, DE); Endert, Gerold (Halle, DE) |
| Assignees: |
NOVOSOM AG (Halle, DE) |
| Claim: |
1.-29. (canceled) |
| Claim: |
30. An amphoteric liposome comprising at least one positive charge carrier, at least one negative charge carrier, and at least one neutral lipid, wherein the liposome has an isoelectric point of between 4 and 8, and wherein the liposome is stable at pH 4.2 and pH 7.5. |
| Claim: |
31. The amphoteric liposome of claim 30, wherein the liposome has an isoelectric point of between 5 and 7. |
| Claim: |
32. The amphoteric liposome of claim 30, wherein the neutral lipid is selected from the group consisting of phosphatidyl choline, phosphatidyl ethanolamine, cholesterol, tetraether lipid, ceramide, sphingolipid, and diacyl glycerol. |
| Claim: |
33. An amphoteric liposome comprising at least one amphoteric charge carrier having an isoelectric point of between 4 and 8, wherein the liposome comprises at least one neutral lipid, and wherein the liposome is stable at pH 4.2 and pH 7.5. |
| Claim: |
34. The amphoteric liposome of claim 33, wherein the amphoteric charge carrier has an isoelectric point of between 5 and 7. |
| Claim: |
35. The amphoteric liposome of claim 33, wherein the neutral lipid is selected from the group consisting of phosphatidyl choline, phosphatidyl ethanolamine, cholesterol, tetraether lipid, ceramide, sphingolipid, and diacyl glycerol. |
| Claim: |
36. The amphoteric liposome of claim 33, further comprising at least one anionic and/or cationic charge carrier. |
| Claim: |
37. The amphoteric liposome of claim 36, wherein the anionic charge carrier is a weak anionic lipid. |
| Claim: |
38. The amphoteric liposome of claim 36, wherein the cationic charge carrier is a strong cationic lipid. |
| Claim: |
39. The amphoteric liposome of claim 37, wherein the weak anionic lipid is selected from the group consisting of cholesterol hemisuccinate (CHEMS), diacyl glycerol hemisuccinate, fatty acids and phosphatidylserine. |
| Claim: |
40. The amphoteric liposome of claim 38, wherein the strong cationic lipid is selected from the group consisting of DOTAP, DC-Chol, DORIE, DDAB, TC-Chol, DOTMA, DOGS, (C18)2Gly+N,N-dioctadecylamino-glycin, CTAB, CPyC and DOEPC. |
| Claim: |
41. The amphoteric liposome of claim 36, wherein the cationic charge carrier is a weak cationic lipid. |
| Claim: |
42. The amphoteric liposome of claim 41, wherein the weak cationic lipid is selected from the group consisting of HisChol and MoChol. |
| Claim: |
43. The amphoteric liposome of claim 36, wherein the anionic charge carrier is a strong anionic lipid. |
| Claim: |
44. The amphoteric liposome of claim 43, wherein the strong anionic lipid is selected from the group consisting of cholesterol sulphate, cholesterol phosphate, phosphatidylglycerol, phosphatidic acid, phosphatidyl inositol, and cetyl phosphate. |
| Claim: |
45. The amphoteric liposome of claim 30 or claim 33, wherein the liposome has an average size of between 50 and 1000 nm. |
| Claim: |
46. The amphoteric liposome of claim 45, wherein the liposome has an average size of between 70 and 250 nm. |
| Claim: |
47. The amphoteric liposome of claim 45, wherein the liposome has an average size of between 60 and 130 nm. |
| Claim: |
48. The amphoteric liposome of claim 30 or claim 33, wherein the liposome comprises an active ingredient. |
| Claim: |
49. The amphoteric liposome of claim 48, wherein the active ingredient is a protein, a peptide, a DNA, an RNA, antisense nucleotide, or a decoy nucleotide. |
| Claim: |
50. The amphoteric liposome of claim 48, wherein at least 80 percent of the active ingredient is in the interior of the liposome. |
| Current U.S. Class: |
424/450 |
| Current International Class: |
61; 61; 61 |
| رقم الانضمام: |
edspap.20110293695 |
| قاعدة البيانات: |
USPTO Patent Applications |